Loading...
•
Sep 30, 2023
Scholar Rock Q3 2023 Earnings Report
Scholar Rock's pipeline advanced, SRK-181 showed therapeutic potential, and completed a public offering.
Key Takeaways
Scholar Rock reported a net loss of $42.4 million for Q3 2023, with no revenue recorded. The company completed enrollment for the Phase 3 SAPPHIRE trial and presented data supporting SRK-181. A $98 million public offering was completed, extending the cash runway into the second half of 2025.
Completed enrollment for pivotal Phase 3 SAPPHIRE trial evaluating apitegromab.
Expanded into cardiometabolic disorders with SRK-439, a novel investigational myostatin inhibitor.
Presented new data supporting proof of concept for SRK-181 in heavily pretreated patients with resistant metastatic ccRCC.
Completed $98 million public offering, extending projected cash runway into second half of 2025.
Forward Guidance
Scholar Rock is focused on advancing its pipeline and expects the cash runway to extend well past the SAPPHIRE Phase 3 data readout in Q4 2024.
Positive Outlook
- Completing enrollment of the Phase 3 SAPPHIRE trial.
- Advancing SRK-439 into cardiometabolic disorders.
- Presenting new data supporting proof of concept for SRK-181.
- Completing $98 million public offering.
- Extending projected cash runway into second half of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...